Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

ClinicalTrials.gov ID: NCT02817633

Public ClinicalTrials.gov record NCT02817633. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)

Study identification

NCT ID
NCT02817633
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Tesaro, Inc.
Industry
Enrollment
463 participants

Conditions and interventions

Conditions

Interventions

  • TSR-022 Drug
  • Nivolumab Drug
  • TSR-042 Drug
  • TSR-033 Drug
  • Docetaxel Drug
  • Pemetrexed Drug
  • Cisplatin Drug
  • Carboplatin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 7, 2016
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027
Last update posted
Oct 27, 2025

2016 – 2027

United States locations

U.S. sites
64
U.S. states
27
U.S. cities
59
Facility City State ZIP Site status
GSK Investigational Site Goodyear Arizona 85338
GSK Investigational Site Scottsdale Arizona 85258
GSK Investigational Site Tucson Arizona 85704
GSK Investigational Site Tucson Arizona 85711
GSK Investigational Site Encinitas California 92024
GSK Investigational Site Fountain Valley California 92708
GSK Investigational Site Los Angeles California 90024
GSK Investigational Site Los Angeles California 90025
GSK Investigational Site San Marcos California 92069
GSK Investigational Site Whittier California 90606
GSK Investigational Site Aurora Colorado 80012
GSK Investigational Site Aurora Colorado 80045
GSK Investigational Site Denver Colorado 80218
GSK Investigational Site New Haven Connecticut 06511
GSK Investigational Site Washington D.C. District of Columbia 20007
GSK Investigational Site Jacksonville Florida 32224
GSK Investigational Site Miami Florida 33140
GSK Investigational Site Sarasota Florida 34232
GSK Investigational Site Tampa Florida 33612
GSK Investigational Site Atlanta Georgia 30322
GSK Investigational Site Augusta Georgia 30912
GSK Investigational Site Arlington Heights Illinois 60005
GSK Investigational Site Chicago Illinois 60637
GSK Investigational Site Niles Illinois 60714
GSK Investigational Site Iowa City Iowa 52242
GSK Investigational Site Wichita Kansas 67214
GSK Investigational Site Louisville Kentucky 40202
GSK Investigational Site Pikeville Kentucky 41501
GSK Investigational Site Wheaton Maryland 20850
GSK Investigational Site Boston Massachusetts 02114
GSK Investigational Site Detroit Michigan 48202
GSK Investigational Site Rochester Minnesota 55905
GSK Investigational Site Florissant Missouri 63031
GSK Investigational Site St Louis Missouri 63110
GSK Investigational Site St Louis Missouri 63129
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Hackensack New Jersey 07601
GSK Investigational Site New York New York 10016
GSK Investigational Site The Bronx New York 10461
GSK Investigational Site Cincinnati Ohio 45242
GSK Investigational Site Cleveland Ohio 44106
GSK Investigational Site Toledo Ohio 43623
GSK Investigational Site Eugene Oregon 97401
GSK Investigational Site Vancouver Oregon 97213-2982
GSK Investigational Site Bethlehem Pennsylvania 18015
GSK Investigational Site Pittsburgh Pennsylvania 15232
GSK Investigational Site Charleston South Carolina 29425
GSK Investigational Site Greenville South Carolina 29605
GSK Investigational Site Nashville Tennessee 37203
GSK Investigational Site Austin Texas 78705
GSK Investigational Site Dallas Texas 75246
GSK Investigational Site Fort Worth Texas 76104
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Longview Texas 75601
GSK Investigational Site McAllen Texas 78503-1298
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Temple Texas 76508
GSK Investigational Site Tyler Texas 75702
GSK Investigational Site Fairfax Virginia 22031
GSK Investigational Site Kennewick Washington 99336
GSK Investigational Site Puyallup Washington 98373
GSK Investigational Site Seattle Washington 98111
GSK Investigational Site Tacoma Washington 98405
GSK Investigational Site Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02817633, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 27, 2025 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02817633 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →